|
Volumn 18, Issue 4, 2010, Pages 1711-1723
|
Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) Scaffold: Exploration of P1′ alkoxy residues and an aminoethylene (AE) central core
b
MEDIVIR AB
(Sweden)
|
Author keywords
Alzhemier's disease; Aminoethylene (AE) isostere; BACE 1 inhibitors; Hydroxyethylene (HE) isostere; P1 modifications; Peptidomimetics
|
Indexed keywords
AMINO ACID DERIVATIVE;
BETA SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 INHIBITOR;
CATHEPSIN D;
ETHYLENE DERIVATIVE;
HYDROXYL GROUP;
N [1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 4 BENZYL 1 (3,5 DIFLUOROPHENOXYMETHYL) 2 HYDROXYBUTYL] 5 (METHANESULFONYL AMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 1 (3,5 DIFLUOROPHENOXYMETHYL) 2 HYDROXY 4 (2 METHOXYETHOXY)BUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 1 (3,5 DIFLUOROPHENOXYMETHYL) 2 HYDROXY 4 METHOXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 1 (3,5 DIFLUOROPHENOXYMETHYL) 4 ETHYL 2 HYDROXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 1 (3,5 DIFLUOROPHENOXYMETHYL) 4 METHOXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 2 AMINO 1 (3,5 DIFLUOROPHENOXYMETHYL) 4 METHOXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 4 CYCLOPROPYLMETHOXY 1 (3,5 DIFLUOROPHENOXYMETHYL) 2 HYDROXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 4 OXY 1 (3,5 DIFLUOROPHENOXYMETHYL) 2 HYDROXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N' (1 PHENYLETHYL)ISOPHTHALAMIDE;
N [4 (1 BENZYLCARBAMOYL 2 METHYLPROPYLCARBAMOYL) 4 PROPYLOXYBUTYL] 5 (METHANESULFONYLMETHYLAMINO) N (1 PHENYLETHYL)ISOPHTHALAMIDE;
PROTEIN INHIBITOR;
UNCLASSIFIED DRUG;
ARTICLE;
CHEMICAL MODIFICATION;
DEOXYGENATION;
DRUG POTENCY;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
ENZYME INHIBITION;
PROTEIN FOLDING;
PROTEIN MOTIF;
STEREOCHEMISTRY;
STRUCTURE ACTIVITY RELATION;
X RAY CRYSTALLOGRAPHY;
AMYLOID PRECURSOR PROTEIN SECRETASES;
ASPARTIC ACID ENDOPEPTIDASES;
CRYSTALLOGRAPHY, X-RAY;
ENZYME INHIBITORS;
ETHYLENES;
MAGNETIC RESONANCE SPECTROSCOPY;
MODELS, MOLECULAR;
MOLECULAR STRUCTURE;
SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;
SPECTROPHOTOMETRY, ULTRAVIOLET;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 75849154226
PISSN: 09680896
EISSN: None
Source Type: Journal
DOI: 10.1016/j.bmc.2009.12.051 Document Type: Article |
Times cited : (14)
|
References (35)
|